EU GMP Non-Compliance Reports in Brief
This article was originally published in The Gold Sheet
Authorities recently withdrew several EU GMP certificates for various reasons including beta-lactam cross-contamination risk, data integrity lapses, and failure to prepare for a requested inspection.
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.